The Cas9 protein together with RNA and DNA (orange; artist’s illustration). A new therapy uses the CRISPR-Cas9 gene editing system to treat a rare genetic disease called hereditary angioedema.Credit: Alfred Pasieka/SPL A pioneering therapy that edits genes inside a recipient’s body continues to be effective four years after treatment, according to data released by its
WASHINGTON — A plan to give Americans easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with the policy’s development. The document, which covers certain injectable
This summer, every meal feels like a risk. Just as the US is recovering from a major cyclospora outbreak stemming from tainted iceberg lettuce, salmonella has turned up in jalapeños, eggs, and even dog food. The jalapeño-related outbreak is now responsible for at least 431 illnesses and 57 hospitalizations in more than two dozen states.
Trump has praised Overton, a former general surgery resident at Johns Hopkins University School of Medicine and chief policy officer at conservative think tank America First Policy Institute, as a “rockstar” future leader of the FDA. But her nomination to the top job comes at a time where Trump officials are attempting to take steps
FILE – A sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) Manuel Balce Ceneta/AP hide caption toggle caption Manuel Balce Ceneta/AP The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering
The Food and Drug Administration on Wednesday approved Rasonque, a once-daily pill developed by Revolution Medicines to block several forms of the RAS protein — the mutation that drives tumor growth in most pancreatic cancers, and in roughly a quarter of all human cancers overall. For investors like Dr. Danish Nagda, an early shareholder in